Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MR-Imaging and Histopathological Diagnostic Work-Up of Patients with Spontaneous Lobar Intracerebral Hemorrhage: Results of an Institutional Prospective Registry Study.
Schuss P, Bode C, Borger V, Coch C, Güresir Á, Hadjiathanasiou A, Hamed M, Kuchelmeister K, Lehmann F, Müller M, Schneider M, Solymosi L, Vatter H, Velten M, Güresir E. Schuss P, et al. Among authors: coch c. Diagnostics (Basel). 2021 Feb 22;11(2):368. doi: 10.3390/diagnostics11020368. Diagnostics (Basel). 2021. PMID: 33671532 Free PMC article.
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
Tzaridis T, Schäfer N, Weller J, Steinbach JP, Schlegel U, Seidel S, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Tonn JC, Grauer O, Kebir S, Schneider M, Schaub C, Vatter H, Coch C, Glas M, Fimmers R, Pietsch T, Reifenberger G, Herrlinger U, Felsberg J. Tzaridis T, et al. Among authors: coch c. Int J Cancer. 2021 Apr 1;148(7):1695-1707. doi: 10.1002/ijc.33363. Epub 2020 Nov 10. Int J Cancer. 2021. PMID: 33113214 Free article. Clinical Trial.
Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage (FINISHER) trial: Study protocol for a randomized controlled trial.
Güresir E, Lampmann T, Bele S, Czabanka M, Czorlich P, Gempt J, Goldbrunner R, Hurth H, Hermann E, Jabbarli R, Krauthausen M, König R, Lindner D, Malinova V, Meixensberger J, Mielke D, Németh R, Darkwah Oppong M, Pala A, Prinz V, Rashidi A, Roder C, Sandalcioglu IE, Sauvigny T, Schebesch KM, Timmer M, Vajkoczy P, Wessels L, Wild F, Wilhelm C, Wostrack M, Vatter H, Coch C. Güresir E, et al. Among authors: coch c. Int J Stroke. 2023 Feb;18(2):242-247. doi: 10.1177/17474930221093501. Epub 2022 May 3. Int J Stroke. 2023. PMID: 35361026
Aneurysmal Subarachnoid Hemorrhage during the Shutdown for COVID-19.
Güresir E, Gräff I, Seidel M, Bauer H, Coch C, Diepenseifen C, Dohmen C, Engels S, Hadjiathanasiou A, Heister U, Heyer I, Lampmann T, Paus S, Petzold G, Pöhlau D, Putensen C, Schneider M, Schuss P, Textor J, Velten M, Wach J, Welchowski T, Vatter H. Güresir E, et al. Among authors: coch c. J Clin Med. 2022 May 2;11(9):2555. doi: 10.3390/jcm11092555. J Clin Med. 2022. PMID: 35566681 Free PMC article.
PrImary decompressive Craniectomy in AneurySmal Subarachnoid hemOrrhage (PICASSO) trial: study protocol for a randomized controlled trial.
Güresir E, Lampmann T, Brandecker S, Czabanka M, Fimmers R, Gempt J, Haas P, Haj A, Jabbarli R, Kalasauskas D, König R, Mielke D, Németh R, Oppong MD, Pala A, Prinz V, Ringel F, Roder C, Rohde V, Schebesch KM, Wagner A, Coch C, Vatter H. Güresir E, et al. Among authors: coch c. Trials. 2022 Dec 20;23(1):1027. doi: 10.1186/s13063-022-06969-4. Trials. 2022. PMID: 36539817 Free PMC article.
Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.
Coenen M, Hinze AV, Mengel M, Fuhrmann C, Lüdenbach B, Zimmermann J, Dykstra V, Fimmers R, Viviani R, Stingl J, Holdenrieder S, Müller M, Hartmann G, Coch C. Coenen M, et al. Among authors: coch c. BMC Pharmacol Toxicol. 2015 Sep 22;16:25. doi: 10.1186/s40360-015-0025-x. BMC Pharmacol Toxicol. 2015. PMID: 26392348 Free PMC article. Clinical Trial.
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: coch c. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
72 results